Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-826-9 | CAS number: 100-18-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: older study; not conducted in accordance with GLP guidelines
- Qualifier:
- no guideline followed
- GLP compliance:
- no
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- Rats were given a total of 11 treatments over a 15-day span
- Frequency of treatment:
- once daily
- Remarks:
- Doses / Concentrations:
100 mg/kg
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
1000 mg/kg
Basis:
actual ingested - No. of animals per sex per dose:
- Groups of five male rats were gavaged with 1000 or 100 mg compound/kg/day for a total of eleven treatments over a 15 day span. A control group of five animals were gavaged with distilled water at a dose of 1000 mg/kg/day. Weight gain and feed intake were comparable between groups.
- Control animals:
- yes, sham-exposed
- Observations and examinations performed and frequency:
- Weight gain and feed intake were measured at the beginning and end of the study period
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- a single high-dose animal exhibited porphyrin nasal discharge, weight loss and possible aspiration pneumonia
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- a single high-dose animal exhibited porphyrin nasal discharge, weight loss and possible aspiration pneumonia
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- statistically-significant differences were noted in the high-dose group, including increased platelets and monocytes. All other indices were comparable to controls
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- A moderate decrease in serum glucose and a slight increase in creatinine in the high-dose animals; all other serum chemistry indices were comparable to controls
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- A statistically-significant increase in relative liver weights were observed in the high-dose group
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Enlarged hearts were observed in 3 of 5 rats in the high-dose group, which was considered to have occurred as a result of general respiratory stress associated with extensive consolidation of the lung
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- Weight gain and feed intake were comparable between groups. No abnormal clinical signs were observed with the exception of a single high-dose animal which exhibited porphyrin nasal discharge, weight loss, and possible aspiration pneumonia. Several slight but statistically significant differences were noted in hematology in the high dosed group at autopsy. These included a slight increase in platelets and an increased percentage of monocytes. Both increases were dosage related. All other hematological parameters (red blood cell count, hemoglobin concentration, hematocrit, red cell indices, white blood cell counts and the remaining portions of the differential white blood cell count) were comparable to controls. There was a moderate decrease in serum glucose and a slight increase in creatinine in the high dosed animals, but all other serum clinical chemistries (alanine aminotransferase, aspartate aminotransferase, sorbitol dehydrogenase, alkaline phosphatase, and urea nitrogen) were unaffected by treatment. No alterations in hematology or serum clinical chemistry were noted in blood from the low dose group.
No significant changes in absolute or relative kidney or spleen weights were noted. There was, however, a trend which implied a dose dependent increase in both absolute and relative liver weights. The relative liver weights were statistically significantly increased in the high dose group. Gross pathology examination revealed enlarged hearts in 3/5 high dosed animals but no compound related effects were seen at histopathology examination. The enlarged hearts were observed in animals exhibiting extensive consolidation of the lung. The hearts in these animals may have hypertrophied in response to general respiratory stress resulting from compromise of the lung. The liver may be a site of toxic action, and the no effect level may be in the range of 100 mg/kg. - Key result
- Dose descriptor:
- NOEL
- Effect level:
- ca. 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- gross pathology
- haematology
- ophthalmological examination
- organ weights and organ / body weight ratios
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Conclusions:
- Based upon the results of this study, daily doses of 1000 mg/kg of p-diisopropylbenzene administered via gavage to male rats daily over a 2-week period produced increased relative liver weights and incidental findings in serum chemistry (decreased glucose; increased creatinine) and hematology (increased platelets and % moncytes) but no abnormal histopathological findings. A daily dose of 100 mg/kg was considered to be a no effect level (NOEL).
- Executive summary:
The test article, p-diisopropylbenzene, was evaluated in a 2-week (subacute) oral toxicity study. Groups of five male rats were gavaged with 1000 or 100 mg compound/ kg/day for a total of eleven treatments over a 15 day span. A control group of five animals were gavaged with distilled water at a dose of 1000 mg/kg/day. Weight gain and feed intake were comparable between groups. No abnormal clinical signs were observed with the exception of a single high-dose animal which exhibited porphyrin nasal discharge, weight loss, and possible aspiration pneumonia. Several slight but statistically significant differences were noted in hematology in the high dosed group at autopsy. These included a slight increase in platelets and an increased percentage of monocytes. Both increases were dosage related. All other hematological parameters (red blood cell count, hemoglobin concentration, hematocrit, red cell indices, white blood cell counts and the remaining portions of the differential white blood cell count) were comparable to controls. There was a moderate decrease in serum glucose and a slight increase in creatinine in the high dosed animals, but all other serum clinical chemistries (alanine aminotransferase, aspartate aminotransferase, sorbitol dehydrogenase, alkaline phosphatase, and urea nitrogen) were unaffected by treatment. No alterations in hematology or serum clinical chemistry were noted in blood from the low dose group.
No significant changes in absolute or relative kidney or spleen weights were noted. There was, however, a trend which implied a dose dependent increase in both absolute and relative liver weights. The relative liver weights were statistically significantly increased in the high dose group. Gross pathology examination revealed enlarged hearts in 3/5 high dosed animals but no compound related effects were seen at histopathology examination. The enlarged hearts were observed in animals exhibiting extensive consolidation of the lung. The hearts in these animals may have hypertrophied in response to general respiratory stress resulting from compromise of the lung. The liver may be a site of toxic action, and the no effect level (NOEL) may be in the range of 100 mg/kg.
Reference
Additional information
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live1